Robin Butcher
Family · San Antonio, TXNPI 1982330288
Payments from drug & device makers
Across 801 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Novartis$1K
- Dexcom, Inc.$1K
- Ascensia Diabetes Care US Inc.$1K
- plus $8K from 32 others
What the payments were for
- Travel & lodging$1,5149%
- Food & beverage$16,03891%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 67 | $3,184 |
| Novo Nordisk | 76 | $1,699 |
| Lilly USA, LLC | 80 | $1,526 |
| Novartis | 75 | $1,137 |
| Dexcom, Inc. | 56 | $1,106 |
| Ascensia Diabetes Care US Inc. | 60 | $1,030 |
| Boehringer Ingelheim | 41 | $761 |
| Corcept Therapeutics | 29 | $733 |
| Amgen | 34 | $627 |
| Mannkind Corporation | 40 | $601 |
| Sequel Med Tech, LLC | 38 | $574 |
| Radius Health, Inc. | 30 | $556 |
| Xeris Pharmaceuticals, Inc. | 35 | $518 |
| AstraZeneca(2 entities) | 17 | $510 |
| Cequr Corporation | 3 | $488 |
| Bayer | 26 | $476 |
| Recordati_rare_diseases_inc. | 19 | $325 |
| Kyowa Kirin, Inc. | 12 | $282 |
| Insulet Corporation | 7 | $235 |
| AbbVie | 15 | $225 |
| Sanofi-aventis U.S. LLC | 10 | $202 |
| Ascendis Pharma Endocrinology Inc | 1 | $195 |
| Madrigal Pharmaceuticals | 6 | $121 |
| Antares Pharma, Inc. | 4 | $80 |
| Soleno Therapeutics, Inc. | 2 | $49 |
| Almatica Pharma LLC | 2 | $46 |
| Tolmar, Inc. | 3 | $42 |
| Averitas Pharma Inc. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $22 |
| Halozyme Inc | 1 | $21 |
| Amphastar Pharmaceuticals, Inc. | 1 | $21 |
| GSK | 1 | $21 |
| RGH Enterprises LLC | 1 | $19 |
| Pfizer | 1 | $15 |
| BETA Bionics, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,852
- CeQur Simplicity$399
- DEXCOM G6 TRANSMITTER$293
- TWIIST$284
- FARXIGA$233
- Korlym$224
- TEPEZZA$150
- MINIMED 770G$130
- Omnipod$128
- LEQVIO$127
- Wegovy$125
- MOUNJARO$125
- Kerendia$120
- Ozempic$113
- RYBELSUS$113
How this compares
$17,568 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 25 | $1,236,112 |
| MounjaroTirzepatide | 290 | $404,951 |
| OzempicSemaglutide | 234 | $341,815 |
| TrulicityDulaglutide | 110 | $194,050 |
| AfrezzaInsulin Regular, Human | 66 | $171,833 |
| FarxigaDapagliflozin Propanediol | 149 | $153,969 |
| JardianceEmpagliflozin | 118 | $145,630 |
| TymlosAbaloparatide | 19 | $82,005 |
| Tresiba Flextouch U-100Insulin Degludec | 61 | $47,071 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $45,302 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $42,785 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 32 | $40,111 |
| ProliaDenosumab | 20 | $33,696 |
| RybelsusSemaglutide | 17 | $30,632 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 26 | $18,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $733 | $1,236,11225 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,526 | $615,524452 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,699 | $380,703273 claims |
| Mannkind CorporationAfrezza | $601 | $171,83366 claims |
| AstraZenecaFarxiga | $510 | $153,969149 claims |
| Boehringer IngelheimJardiance | $761 | $145,630118 claims |
| Radius Health, Inc.Tymlos | $556 | $82,00519 claims |
| AmgenProlia | $627 | $33,69620 claims |
| Cequr CorporationCequr Simplicity | $488 | $18,84739 claims |
| AbbVieSynthroid | $225 | $7,62177 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Ayoade AvworoSan Antonio$111K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.